At a journal club sponsored by the George Washington University Departmentof Ophthalmology in March 2003, we read and discussed with great interestthe case series by Jonas et al1 in whichpatients were given intravitreal injections of triamcinolone acetonide fordiffuse diabetic macular edema. Several issues were raised that we would liketo share. The specific areas of concern included visual acuity end point measurementtechnique, possible measurement bias, and low power to detect treatment adverseeffects.
Savage H, Roh M. Safety and Efficacy of Intravitreal Triamcinolone. Arch Ophthalmol. 2004;122(7):1083. doi:10.1001/archopht.122.7.1083-a